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anBACKGROUND It is uncertain whether a diagnostic strategy supplemented by early coronary computed tomography
angiography (CCTA) is superior to contemporary standard optimal care (SOC) encompassing high-sensitivity troponin
assays (hs-troponins) for patients suspected of acute coronary syndrome (ACS) in the emergency department (ED).
OBJECTIVES This study assessed whether a diagnostic strategy supplemented by early CCTA improves clinical
effectiveness compared with contemporary SOC.
METHODS In a prospective, open-label, multicenter, randomized trial, we enrolled patients presenting with symp-
toms suggestive of an ACS at the ED of 5 community and 2 university hospitals in the Netherlands. Exclusion criteria
included the need for urgent cardiac catheterization and history of ACS or coronary revascularization. The primary
endpoint was the number of patients identiﬁed with signiﬁcant coronary artery disease requiring revascularization
within 30 days.
RESULTS The study population consisted of 500 patients, of whom 236 (47%) were women (mean age 54  10 years).
There was no difference in the primary endpoint (22 [9%] patients underwent coronary revascularization within 30 days
in the CCTA group and 17 [7%] in the SOC group [p ¼ 0.40]). Discharge from the ED was not more frequent after CCTA
(65% vs. 59%, p ¼ 0.16), and length of stay was similar (6.3 h in both groups; p ¼ 0.80). The CCTA group had lower
direct medical costs (V337 vs. V511, p < 0.01) and less outpatient testing after the index ED visit (10 [4%] vs. 26 [10%],
p < 0.01). There was no difference in incidence of undetected ACS.
CONCLUSIONS CCTA, applied early in the work-up of suspected ACS, is safe and associated with less outpatient
testing and lower costs. However, in the era of hs-troponins, CCTA does not identify more patients with signiﬁcant CAD
requiring coronary revascularization, shorten hospital stay, or allow for more direct discharge from the ED.
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AB BR E V I A T I O N S
AND ACRONYM S
ACS = acute coronary
syndrome
CAD = coronary artery disease
CCTA = coronary computed
tomography angiography
CT = computed tomography
ECG = electrocardiogram
ED = emergency department
ExECG = exercise
electrocardiography
hs-troponins = high-
sensitivity troponin assays
ICA = invasive coronary
angiography
SOC = standard optimal care
SPECT = single-photon
emission computed
tomography
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17A cute chest pain can herald severe cardiovas-cular conditions, such as an acute coronarysyndrome (ACS) (1). However, the differential
diagnosis of acute chest pain is broad, and the conse-
quences of misdiagnosis can be detrimental (2–4).
Physicians confront this diagnostic dilemma daily.
Coronary computed tomography angiography (CCTA)
allows noninvasive visualization of the coronary ar-
teries (5). Because of its high accuracy in ruling out cor-
onary artery disease (CAD), CCTA has been proposed
for better decision making in the emergency depart-
ment (ED), allowing for rapid discharge of patients
without important CAD and, possibly, more appro-
priate referral for coronary revascularization (6,7).
Early CCTA as a diagnostic strategy in low- to
intermediate-risk patients suspected of ACS is consid-
ered safe and may provide logistic and economic ben-
eﬁts (8–10). Meanwhile, high-sensitivity troponin
assays (hs-troponins) have become standard practice
in many institutions, allowing for more accurate and
faster rule-out of ACS (11,12). Whether hs-troponins
will erode the potential clinical, logistic, and economic
beneﬁts of CCTA has not yet been investigated. The
BEACON (Better Evaluation of Acute Chest Pain with
Coronary Computed Tomography Angiography) trial
is a European randomized trial comparing a diagnostic
strategy supplemented by early CCTA with standard
optimal care (SOC) for patients suspected of ACS in
the era of hs-troponins.SEE PAGE 27METHODS
STUDY DESIGN. The BEACON study is a prospective,
open-label, multicenter, randomized trial. Patients
were enrolled at 2 university and 5 community hos-
pitals in the Netherlands. Enrollment was performed
during working hours, except at the Erasmus Medical
Center University Medical Centre, where patients
were included around the clock. The study complied
with the CONSORT 2010 Statement and Declaration of
Helsinki, and was approved by the institutional ethics
committees of each participating center. All patients
provided written informed consent.
PARTICIPANTS. Patients with acute chest pain
or symptoms suggestive of ACS warranting further
diagnostic evaluation, as determined by the treating
physician, were eligible for inclusion. We includedand nonﬁnancial support from Siemens Medical Solutions. All other auth
relevant to the contents of this paper to disclose.
Manuscript received May 10, 2015; revised manuscript received August 26,patients 30 years of age and older, with a
maximum age of 75 years for men and 80
years for women. Patients were excluded if
symptoms were clearly of noncardiac origin
or a coexisting condition already necessitated
hospital admission. Exclusion criteria also
included a history of known CAD, clinical
need for urgent invasive coronary angiog-
raphy (ICA), clinical instability, serum
troponin levels above 3 times the upper limit
of the 99th percentile of the local assay,
impaired renal function (estimated glomer-
ular ﬁltration rate <60% of age-corrected
normal values), pregnancy, known allergy to
an iodinated contrast agent, severe arrhyth-
mias, and body mass index >40 kg/m2.
RANDOMIZATION. Trial participants were
randomly assigned to a CCTA-based diag-
nostic strategy or SOC (1:1). For allocation, a
computer-generated block randomization
sequence was used, stratiﬁed by participating center.
An independent physician at the coordinating center
extracted the randomization schedule from an elec-
tronic randomization tool and codes were sent in
sealed, sequentially numbered, opaque envelopes to
the participating centers.
PROCEDURES. The initial standard clinical work-up
at the ED included a 12-lead electrocardiogram
(ECG) and blood analysis. If the initial clinical
work-up did not reveal either an evident ACS or an
evident noncardiac cause, eligible and consenting
patients were randomized between a CCTA-guided
strategy and SOC. In the intervention group, CCTA
was performed after the initial clinical work-up at the
ED. In both groups, hs-troponins were available
(Online Table 1). Image acquisition was performed on
64-slice or a more advanced computed tomography
(CT) system, using ECG-synchronized axial or spiral
scan protocols combined with radiation minimizing
measures, depending on local practices, available
technology, and patient characteristics. Results of
CCTA were reported by certiﬁed radiologists with a
minimum of 2 years of experience reading CCTA.
Treating physicians were informed directly at the
point of care regarding the result of CCTA and
imaging-based recommendations were issued. Final
medical management decisions were, however, left to
the treating physicians (Figure 1). In the SOC group,ors have reported that they have no relationships
2015, accepted October 20, 2015.
FIGURE 1 Trial Proﬁle
Suspected acute coronary syndrome
Initial standard clinical workup
History
Physical examination
12-lead ECG
Blood analysis
Clear non-cardiac cause of symptoms
Coexisting condition necessitating hospital admission
Very likely or definitive ACS
ST-segment-elevation myocardial infarction
Elevated troponins (>3 times upper limit of 99th percentile)
Clinical need for ICA
Severe arrhythmias
Clinical instabilityExcluded
History of known CAD
Impaired renal function
Pregnancy
Known allergy to an iodinated contrast agent
Body mass index >40 kg/m2
Eligible for inclusion
Study group Control group
CCTA
Standard Optimal Care
Directed by treating physician according to current guidelines
Includes repeated cardiac markers, hospital admission, non-invasive testing and referral to ICANormal CAD+
(<50%)
CAD+
(50-70%)
CAD+
(≥70%)
Nondiagnostic
Discharge from ED
Repeated cardiac markers
Repeated cardiac markers
Additional functional testing or referral to ICA
Repeated cardiac markers
Referral to ICA
Repeated cardiac markers
Additional functional testing or referral to ICA
In the study group, CCTA results were reported at the point of care, with imaging-based recommendations as displayed. However, the ﬁnal decision regarding clinical work-up was left to the discretion of the treating
physicians. Impaired renal function was classiﬁed as an estimated glomerular ﬁltration rate <60% of the age-corrected normal values. ACS ¼ acute coronary syndrome; CAD ¼ coronary artery disease; CCTA ¼ coronary
computed tomography angiography; ECG ¼ electrocardiogram; ED ¼ emergency department; ICA ¼ invasive coronary angiography.
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19the attending physicians made clinical decisions
regarding further testing, including repeated cardiac
marker assessment, hospital admission, noninvasive
tests, and referral to ICA, according to current
guidelines (13,14). Participants from both groups who
were discharged from the ED, without prolonged
observation (<8 h) were asked to return to the
outpatient clinic after 48 to 72 h for repeated mea-
surement of cardiac biomarkers and a 12-lead ECG. All
participants were followed-up at the outpatient clinic
or contacted by telephone after 30 days.
OUTCOME MEASURES. The pre-deﬁned primary
endpoint of the study was the number of patients
identiﬁed with signiﬁcant CAD requiring coronary
revascularization, as interpreted by the clinical oper-
ators, within the follow-up period of 30 days. This
outcome parameter was chosen on the basis of the
hypothesis that a CCTA-driven strategy would identify
more clinically important CAD, as suggested by the
results of our single-center pilot study, which could
effectuate a prognostic beneﬁt (15). The use of frac-
tional ﬂow reserve for ischemia-proven coronary
revascularizationwas encouraged, but notmandatory.
This study was set up as a pragmatic clinical trial
focusing on initial ED management without
protocol-mandated medical management during the
remaining clinical course. Secondary endpoints
included expedited discharge rate from the ED, length
of hospital stay, undetected ACS, cumulative radiation
exposure, direct medical costs, and repeat visits to the
ED or rehospitalization for recurrent chest pain within
30 days of follow-up. We deﬁned expedited discharge
as discharge within 8 h from the ED, and length of stay
as the time from presentation in the ED until hospital
discharge. The treating physician made the decision to
discharge. ACS was deﬁned as either unstable angina
pectoris or myocardial infarction, according to current
guidelines (16). The diagnosis of ACS was not on the
basis of the CCTA results. The occurrence of unde-
tected ACS was assessed at both the safety follow-up
within 72 h and the general follow-up at 30 days. Cu-
mulative radiation exposure was expressed in milli-
sieverts (mSv) and deﬁned as radiation exposure from
all tests and interventions undergone within the ﬁrst
30 days, including CCTA, single-photon emission
computed tomography (SPECT) myocardial perfusion
imaging, and ICA. Effective radiation dose was derived
by multiplying the dose-length product by a conver-
sion factor of 0.014 for CCTA, 0.0085 mSv/mBq for
SPECT and 0.22 mSv/Gy  cm2 for ICA. To estimate the
radiation dose of procedures without reported expo-
sure data, the median radiation dose per procedure
was used. Direct medical costs during the index visit
and within the follow-up period of 30 days wereassessed using reports from the Erasmus MC Univer-
sity Medical Centre cost-accounting system in 2013
in Euros (additional information in the Online
Appendix). Finally, we compared the occurrence of
total major adverse cardiac events within 30 days,
deﬁned as death, ACS, and coronary revascularization.
Information on clinical events, repeat visits to the ED,
rehospitalization for recurrent chest pain, diagnostic
testing, or interventions was veriﬁed by medical re-
cords. An adjudication committee consisting of 2
certiﬁed, independent cardiologists reviewed medical
records of patients with clinically relevant events and
a random 10% sample of patients without a diagnosis
of cardiac disease.
STATISTICAL ANALYSIS. Statistical analyses were
performed on the basis of an intention-to-treat anal-
ysis. Continuous data are presented as mean  SD or
medians with interquartile ranges. Independent
samples Student t test or Mann-Whitney U test were
used for between-group comparisons for continuous
variables, and chi-square or Fisher exact test was
used for categorical variables. A 2-sided p value <0.05
was considered to indicate statistical signiﬁcance. For
statistical analyses, we used SPSS version 20.0.
On the basis of our previous observational data, we
anticipated an absolute 9% increase in the number of
coronary revascularizations if the results of CCTA
were to be incorporated (15). Considering an a ¼ 0.05
and b ¼ 0.8 with an intervention versus control group
enrollment ratio of 1:1, and allowing a loss to follow-
up of approximately 10%, we would require 500
participants to detect a difference in the number of
patients requiring revascularization of relevant CAD.
RESULTS
Between July 11, 2011, and January 30, 2014, 573
eligible patients were approached for the study; 73
(13%) declined to participate (Figure 2). In total, 7
patients in the CCTA group did not have a CT scan,
and 6 patients in the SOC group eventually under-
went a CT examination to exclude either CAD or other
vascular conditions. At 30 days, 5 patients in each
group had withdrawn from the study, resulting in
complete follow-up in 490 (98%) patients.
STUDY POPULATION. Table 1 shows patient de-
mographics, clinical characteristics, and medical
treatment at baseline. The mean age of the study
population was 54  10 years and 236 (47%) partici-
pants were women. Baseline characteristics and
clinical status were similar between the 2 groups. In
the intervention group, CCTA identiﬁed 106 (42%)
patients with no detectable CAD. Among the patients
with CAD on CCTA, 71 (28%) had atherosclerotic
FIGURE 2 Enrollment, Randomization, and Follow-Up of Study Participants
573 eligible patients approached for the study
73 declined to participate
500 patients underwent randomization
Standard Optimal Care (n=250) CCTA group (n=250)
5 withdrawal / loss to follow-up5 withdrawal / loss to follow-up
6 underwent CT:
1 suspected aortic dissection
2 suspected pulmonary embolism
3 CCTA
7 CCTA not performed:
1 insufficient breath holding ability
2 potential contrast allergy reported after randomization
2 logistic reasons
1 no venous access obtained
1 renal insufficiency after randomization
245 follow-up at 30 days (98%) 245 follow-up at 30 days (98%)
CT ¼ computed tomography; CCTA ¼ coronary computed tomography angiography.
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20plaque with <50% luminal narrowing, 35 (14%) had
50% to 70% luminal narrowing in 1 or more coronary
arteries, and 13 (5%) had $70% luminal narrowing in
1 or more coronary arteries. The scan was considered
nondiagnostic in 18 patients (7%). The mean radiation
dose in the CCTA group was 7.3  6.6 mSv versus
2.6  6.5 mSv in the SOC group.
PRIMARY OUTCOME AND CLINICAL ENDPOINTS. For
the primary outcome, the number of patients requiring
revascularization within 30 days, no difference was
observed between the CCTA group and SOC, that is, 22
(9%) versus 17 (7%) (p ¼ 0.40) (Table 2). Also, the total
number of ICAs performed within 30 days was similar.
At hospital discharge, 22 (9%) patients in the CCTA
group and 17 (7%) in the SOC group were diagnosed
with ACS (p¼ 0.40). Repeat visits to the ED occurred in
13 (5%) patients in the CCTA group, compared with 19
(8%) in the SOC group (p ¼ 0.27). At 30 days, a similarincidence of total major adverse cardiac events, that is,
25 (10%) in the CCTA group and 21 (9%) in the SOC
group was observed (p ¼ 0.54).
SAFETY ENDPOINTS. Undetected ACS occurred once
(0.5%) in the CCTA group and 3 times (1%) in the
SOC group within the 30-day follow-up period
(p ¼ 0.62). In the CCTA group, 1 patient had recur-
rent chest pain with ECG changes suggestive of
myocardial ischemia at his safety visit. In the SOC
group, 1 patient returned with recurrent complaints,
and underwent coronary revascularization following
an abnormal exercise electrocardiography (ExECG)
result. Another patient reported intermittent chest
pain at his safety visit within 72 h and his laboratory
tests showed elevated cardiac biomarkers. The third
patient returned after 5 days with recurrent com-
plaints and elevated cardiac biomarkers. One patient
in the CCTA group died of a hemorrhagic stroke
TABLE 1 Baseline Characteristics
CCTA (n ¼ 250) SOC (n ¼ 250) p Value
Age, yrs 55  10 53  9 0.07
Sex, female 123 (49) 113 (45) 0.37
Medication
Statin 65 (26) 51 (20) 0.14
Aspirin 48 (19) 35 (14) 0.12
Beta-blocker 41 (16) 40 (16) 0.90
ACE inhibitor 29 (12) 29 (12) 1.00
Angiotensin-receptor blocker 18 (7) 17 (7) 0.86
Calcium-channel blocker 18 (7) 19 (8) 0.86
Diuretic agent 36 (14) 23 (9) 0.07
Oral antidiabetic agent 22 (9) 24 (10) 0.76
Insulin 6 (2) 3 (1) 0.31
Cardiovascular risk factors
Diabetes mellitus 31 (12) 33 (13) 0.79
Hypertension 0.95
>150 mm Hg systolic or
>90 mm Hg diastolic
43 (17) 43 (17)
Treated 66 (26) 69 (28)
Hypercholesterolemia 0.31
Total cholesterol >5 mmol/l 25 (10) 35 (14)
Treated 65 (26) 52 (21)
Smoking 0.26
Current 93 (37) 78 (31)
Stopped >1 yr 25 (10) 22 (9)
History of cardiovascular disease 0.95
Peripheral artery disease 8 (3) 7 (3)
TIA/CVA 16 (7) 17 (7)
Family history 112 (45) 98 (39) 0.21
Blood pressure, mm Hg
Systolic 140  19 141  20 0.67
Diastolic 82  12 82  11 0.63
Heart rate, beats/min 72  14 72  13 0.86
TIMI risk score (17) 1 (0–2) 1 (0–2) 0.31
0 74 83
1 84 91
$2 92 76
Grace risk score (18) 85 (70–100) 81 (67–98) 0.28
Low 211 (84) 208 (83) 0.20
Intermediate 31 (12) 39 (16)
High 8 (3) 3 (1)
Ischemic ECG abnormalities 60 (24) 44 (18) 0.08
Baseline troponins elevated* 11 (4) 13 (5) 0.67
Values are mean  SD, n (%), or median (interquartile range). Diabetes mellitus is deﬁned as
plasma glucose >11.0 mmol/l or treated with either diet regulation or medication. Ischemic ECG
abnormalities are deﬁned as Q-wave or ST–T-segment alterations suggestive of ischemia.
*Elevated within 3 times the upper limit of the 99th percentile.
ACE ¼ angiotensin-converting enzyme; CCTA ¼ coronary computed tomography angiography;
CVA ¼ cerebrovascular accident; ECG ¼ electrocardiogram; SOC ¼ standard optimal care; TIA ¼
transient ischemic attack; TIMI ¼ Thrombosis In Myocardial Infarction.
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21following emergency thrombolysis for occlusive
peripheral artery disease 11 days after the index
ED visit.
Nine CCTA examinations (4%) had minor com-
plications: 3 patients had self-limiting, transient
increases in their creatinine levels, 4 patients expe-
rienced contrast medium extravasation without clin-
ical consequences, and 2 had mild, medically treated
allergic skin reactions. In the SOC group, 1 patient
who was discharged early had a transient increase in
the creatinine level at his safety visit.
DIAGNOSTIC TESTING AND RESOURCE UTILIZATION.
More patients were discharged immediately from the
ED after CCTA (159 [65%] vs. 144 [59%]), although
this difference did not reach statistical signiﬁcance
(p ¼ 0.16) (Table 3). The median length of stay
was similar in both groups. ExECG was the most
commonly performed alternative noninvasive diag-
nostic test. In the CCTA group, 32 (13%) patients
underwent ExECG within 30 days: 3 (9%) were sus-
pected of ischemia and 10 (31%) were nondiagnostic.
In the SOC group, 143 (58%) patients underwent
ExECG within 30 days: 9 (6%) were suspected of
ischemia and 39 (27%) were nondiagnostic (Online
Table 2). Outpatient testing was less frequently per-
formed in the CCTA group (10 [4%] vs. 26 [11%];
p < 0.01), and direct medical costs after 30 days were
lower (V337 [V337 to V932] vs. V511 [V309 to V916];
p < 0.01).
DISCUSSION
In this prospective, open-label, multicenter, ran-
domized trial, we compared a diagnostic strategy
supplemented by early CCTA with contemporary SOC
encompassing hs-troponins. In a European setting,
early CCTA was safe, less expensive, with less sub-
sequent outpatient testing than SOC alone. However,
a diagnostic strategy supplemented by early CCTA did
not identify more patients with signiﬁcant CAD
requiring coronary revascularization, reduce the
length of stay, or allow more expedited discharge
from the ED (Central Illustration).
CCTA IN THE ED. Initial observational studies
showed that CCTA was feasible and could safely be
performed in the ED (19,20). The ROMICAT (Rule Out
Myocardial Infarction using Computer Assisted To-
mography) study, where 50% of patients with acute
chest pain were free from any CAD, demonstrated
high negative predictive value and underlined the
potential of CCTA in this setting (6). Because CCTA
identiﬁes the presence of nonobstructive coronary
atherosclerotic plaque, it also may provide the basis
for preventive therapeutic medical measures, asopposed to SPECT or ExECG, which detect the pres-
ence of existing myocardial ischemia (21). In the
current study, nonobstructive coronary atheroscle-
rosis was found in 28% of patients, warranting pre-
ventive management, which would be overlooked
with SOC.
TABLE 3
Length of
Discharge
Discharg
depa
Admitte
ExECG at
ExECG <3
SPECT at
SPECT <3
CMR at in
CMR <30
CCTA afte
Outpatien
test
Cost, V
Values are m
outpatient s
CMR ¼ ca
single-phot
as in Table
TABLE 2 Primary Outcome and Clinical Endpoints Within 30 Days
After Index Visit
CCTA SOC p Value
Invasive coronary angiography* 41 (17) 31 (13) 0.20
Invasive coronary angiography at index visit 34 (14) 25 (10) 0.21
Coronary revascularization* 22 (9) 17 (7) 0.40
Percutaneous coronary intervention 22 (9) 13 (5)
Coronary artery bypass graft surgery 0 4 (2)
Acute coronary syndrome at discharge 22 (9) 17 (7) 0.40
Unstable angina 8 (3) 3 (1) 0.64
Myocardial infarction 14 (6) 14 (6)
Repeat emergency department visit 13 (5) 19 (8) 0.27
Repeat hospital admission 7 (3) 14 (6) 0.12
Undetected acute coronary syndrome 1 (0) 3 (1) 0.62
Major adverse cardiac event 25 (10) 21 (9) 0.54
All-cause mortality 1 (0) 0 1.0
Values are n (%). Major cardiac adverse event includes all-cause mortality, myocardial infarction,
and coronary revascularization. *Includes procedures at index visit.
Abbreviations as in Table 1.
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22Shortly after these initial studies, randomized
controlled trials were initiated to examine whether a
CCTA-based strategy would be more clinically effec-
tive than current practice. The CT-STAT trial
compared CCTA with nuclear myocardial perfusion
imaging as initial tests in the management of patients
with acute chest pain (10). Investigators reported
a 54% reduction in time to diagnosis and 38%
lower costs of ED care with CCTA. In the ACRIN-PA
(American College of Radiology Imaging Network-
Pennsylvania) trial, investigators left decisions to
perform diagnostic tests in the SOC group to theDiagnostic Testing and Resource Utilization
CCTA SOC p Value
stay, h 6.3 (4.8–11.1) 6.3 (4.5–25.5) 0.80
status 0.16
e from emergency
rtment
159 (65) 144 (59)
d to hospital 86 (35) 101 (41)
index visit 23 (9) 130 (53) <0.01
0 days 32 (13) 143 (58) <0.01
index visit 2 (1) 7 (3) 0.18
0 days 2 (1) 16 (7) <0.01
dex 1 (0) 1 (0) 1.00
days 1 (0) 3 (1) 0.62
r index visit 1 (0) 2 (1) 1.00
t diagnostic
ing <30 days*
10 (4) 26 (11) <0.01
337 (337–932) 511 (309–916) <0.01
edian (interquartile range) or n (%). *Total of ExECG, SPECT, CMR, and CCTA in an
etting after index ED visit.
rdiac magnetic resonance imaging; ExECG ¼ exercise electrocardiography; SPECT ¼
on emission computed tomography myocardial perfusion imaging; other abbreviations
1.discretion of the treating physicians (9). The study
demonstrated that low-risk patients could be safely
discharged with early CCTA twice as often, and CAD
was more likely to be diagnosed with CCTA. The
ROMICAT-2 trial also included a cost analysis,
demonstrating a reduction of the median length of
hospital stay from 26.7 to 8.6 h with early CCTA and a
4-fold higher discharge rate from the ED (47% vs.
12%) without increasing medical expenditure (8).
Since these trials were completed, the introduction
of hs-troponin has changed SOC considerably. These
new assays are more sensitive and reach negative
predictive values of >97% for myocardial infarction
within 3 h (11,12). Early observations indicated
that hs-troponins would allow fast and accurate
exclusion of ACS in a substantial proportion of low- to
intermediate-risk patients, obviating the need for
prolonged observation and in-hospital diagnostic
testing in the absence of elevated high-sensitivity
cardiac biomarkers or precarious ECG abnormalities
(22–24).
CURRENT RESULTS IN PERSPECTIVE. The BEACON
trial was designed to compare the clinical effec-
tiveness of a diagnostic strategy supplemented by
early CCTA with contemporary SOC encompassing
hs-troponins. The current study included a popu-
lation with a higher prevalence of obstructive CAD
on CCTA (19%) compared with previous random-
ized trials. The majority of patients were referred
by a general practitioner, deferring very low-risk
patients or those with noncardiac conditions from
the ED. Furthermore, as mandated by the study
protocol, only patients with acute chest pain or
symptoms suggestive of an ACS warranting further
diagnostic evaluation, as determined by the treat-
ing physician, were eligible for inclusion. Finally,
the inclusion of patients with mildly elevated
troponins probably led to an increased prevalence
of CAD.
A diagnostic strategy supplemented by early CCTA
was inclined to detect more patients with signiﬁcant
CAD requiring coronary revascularization in our
study; however, this was not of statistical signiﬁ-
cance. The results of our logistic endpoints differ
from previous trials, as early performance of CCTA
did not shorten the length of stay, nor reduce the
number of hospital admissions in our study. The
length of stay with early CCTA in this study is com-
parable or even lower than previously reported
(Figure 3). However, the length of stay in our SOC
group was substantially lower (median 6.3 h),
underlining the vigorous improvement of SOC after
the introduction of hs-troponins, and also making it
harder to achieve an improvement with early CCTA.
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23Similarly, as many as 59% of patients in the SOC
group could be discharged from the ED, a proportion
2 to 4 times higher than reported in previous ran-
domized trials with physician-directed standard care
as a comparator. Differences in the Netherlands and
U.S. health care systems may be responsible, to someextent, for the contrast between our observations and
those from previously published studies from the
United States. In the Netherlands, primary care phy-
sicians, who are easily accessible and fully covered by
medical insurance, have an important gatekeeper role
and can defer patients at very low risk or with
FIGURE 3 Length of Stay and Discharge Rate From the ED in the
ACRIN-PA, ROMICAT-2, and BEACON Trials
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24probable noncardiac etiology from the ED, which
avoids overcrowding and likely increased the overall
coronary disease prevalence in our population
(25,26). Furthermore, coverage by Dutch insurance
companies is comparable for elective and emergency
care, and ﬁnancial incentives that stimulate outpa-
tient work-up and testing are in place (27,28). In the
United States, delays in access to care, socialdifferences, and insurance coverage problems in-
crease the number of patients seeking care in the ED
(29,30). In addition, although guidelines allow for
outpatient testing in 48 to 72 h after discharge from
the ED, U.S. physicians are more inclined to achieve a
conclusive work-up for the presence of CAD before
discharge because of the availability of the testing,
poor follow-up, and vulnerability to litigation (31–34).
Testing is typically available only during working
hours, leading to prolonged hospital stays. Nonethe-
less, we believe that the contrasting ﬁndings are
largely explained by the profound effect of the
introduction of hs-troponins in the work-up of sus-
pected ACS (11,12,35).
An attractive consequence of early CCTA in our
study was the reduced number of subsequent outpa-
tient testing and lower medical costs at 30 days.
Outpatient testing was mostly driven by the prefer-
ence of the treating physician to assess the presence of
CAD as the cause of symptoms, which was no longer
necessary if CCTA had been performed at ﬁrst pre-
sentation. Although direct comparison of absolute
costs between studies is difﬁcult, the shorter length of
stay, more frequent use of exercise testing instead of
nuclear imaging, and relatively lower cost of CCTA
likely reduced general medical expenditure in this
study (36). When comparing costs between the 2
groups in our study, some important aspects should be
taken into account. According to the applied hospital
cost-accounting system, CCTA was only slightly more
expensive than ExECG. Nuclear myocardial imaging,
which is substantially more costly than either CCTA or
ExECG in the Netherlands, was more frequently per-
formed in the SOC group. Finally, the higher costs in
the SOC group can likely be attributed to the higher
proportion of admitted patients. The median cost per
patient in the SOC group was not affected by the un-
balanced coronary artery bypass graft distribution.
CLINICAL IMPLICATIONS. There is growing evidence
that patients with hs-troponin values below the 99th
percentile of the upper reference limit have a very low
likelihood of ACS. These patients have a very good
prognosis and very often have a normal functional or
CCTA test (37–39). However, those with levels above
the 99th percentile might beneﬁt from additional
testing (i.e., CCTA or a functional test) where (espe-
cially in those with low clinical risk proﬁle) a negative
test would make the occurrence of cardiovascular
events in the short term very unlikely and the need for
immediate further testing unnecessary. In this light, it
would be of interest for future studies to assess the
value of a tiered approach, where application and
timing of CCTA or test of choice is directly guided by
risk proﬁles and biomarker results.
PERSPECTIVES
COMPETENCY IN SYSTEMS-BASED PRACTICE: CCTA is
proposed as a cost-effective addition to standard optimal care
encompassing hs-troponins assays in the diagnostic evaluation of
patients with suspected acute coronary syndromes.
TRANSLATIONAL OUTLOOK: Further studies encompassing
larger populations and longer follow-up are needed to determine
the value of a tiered approach to patient evaluation and man-
agement, whereby selection of CCTA is guided by risk proﬁles
and biomarker results.
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25STUDY LIMITATIONS. The majority of patients were
enrolled during ofﬁce hours, and round-the-clock
implementation of CCTA in the ED poses practical
challenges. In real-world clinical practice, SOC might
prove more efﬁcient than CCTA for 24-h use.
Extrapolation of our results may be affected by dif-
ferences in CT technology, imaging expertise, local
practices, and cost-accounting systems. The overall
observed incidence of the primary endpoint was
lower than anticipated on the basis of experiences
from our observational study. Although speculative,
we believe that the exceptional sensitivity of
hs-troponins, allowing early and precise detection of
ACS, reduced the incidence of the primary endpoint
in both groups, resulting in an underpowered sample
size. Earlier troponin elevations and expedited cath-
eterization procedures rendered a proportion of
high-risk patients ineligible for study inclusion. In
addition, a substantial proportion of patients (50%)
with obstructive CAD on CCTA were ultimately not
referred for catheterization. Without elevated tropo-
nins, these lesions were probably considered stable,
which would justify optimal medical treatment on the
basis of large coronary revascularization outcome tri-
als (40). Given the low incidence of undetected ACS,
this strategy does not appear to have affected safety.
Inherent to the nature of diagnostic trials, blinding of
patients and treating physicians was not possible,
although study participantswere treated by physicians
who aimed for optimal clinical care, and had no direct
involvement in the design and realization of this
study. The effect of an early CCTA strategy on
long-term downstream testing, resource utilization,
and clinical outcome has yet to be determined.
Although the majority of patients were evaluated with
hs-troponins, 21% entered the studywhen these assays
were not yet available at a number of centers. Finally,
an important and noteworthy disadvantage of CCTA is
the exposure of patients to radiation. However, use ofmore innovative CT technology and dose-saving pro-
tocols resulted in lower radiation exposure compared
with earlier trials (7.3 vs. 14.3 mSv).
CONCLUSIONS
CCTA, applied early in the work-up of suspected ACS,
is safe and associated with less outpatient testing and
lower costs. However, in the era of hs-troponins,
CCTA does not identify more patients with signiﬁ-
cant CAD requiring coronary revascularization, nor
does CCTA shorten hospital stay or allow for more
immediate discharge from the ED.
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